{
  "id": "5e44bc4c48dab47f2600001b",
  "type": "summary",
  "question": "What is the mechanism of action of rogaratinib?",
  "ideal_answer": "Rogaratinib is a highly potent and selective small-molecule pan-fibroblast growth factor receptor (FGFR) inhibitor (FGFR1-4) for oral application currently being investigated in phase 1 clinical trials for the treatment of cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31405822",
    "http://www.ncbi.nlm.nih.gov/pubmed/29451369",
    "http://www.ncbi.nlm.nih.gov/pubmed/30807645"
  ],
  "snippets": [
    {
      "text": "Rogaratinib (BAY 1163877) is a highly potent and selective small-molecule pan-fibroblast growth factor receptor (FGFR) inhibitor (FGFR1-4) for oral application currently being investigated in phase\u20051 clinical trials for the treatment of cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451369",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451369",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In preclinical studies, high tumour FGFR mRNA expression predicted response to rogaratinib, an oral pan-FGFR inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31405822",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In preclinical studies, high tumour FGFR mRNA expression predicted response to rogaratinib, an oral pan-FGFR inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31405822",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rogaratinib (BAY 1163877) is a highly potent and selective small-molecule pan-fibroblast growth factor receptor (FGFR) inhibitor (FGFR1-4) for oral application currently being investigated in phase\u20051 clinical trials for the treatment of cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451369",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30807645",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Rogaratinib ( BAY 1163877 ) is a highly potent and selective small-molecule pan-fibroblast growth factor receptor ( FGFR ) inhibitor ( FGFR1-4 ) for oral application currently being investigated in phase 1 clinical trials for the treatment of cancer",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451369",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of Rogaratinib ( BAY 1163877): a pan-FGFR Inhibitor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29451369",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In preclinical studies, high tumour FGFR mRNA expression predicted response to rogaratinib, an oral pan-FGFR inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31405822",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30807645",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In vitro kinase activity assays demonstrate that rogaratinib potently and selectively inhibits the activity of FGFRs 1, 2, 3 and 4.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30807645",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we evaluated the activity of a novel pan-FGFR inhibitor, rogaratinib, in biochemical, cellular and in vivo efficacy studies in a variety of preclinical cancer models.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30807645",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we evaluated the activity of a novel pan-FGFR inhibitor, rogaratinib, in biochemical, cellular and in vivo efficacy studies in a variety of preclinical cancer models.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30807645",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In vitro kinase activity assays demonstrate that rogaratinib potently and selectively inhibits the activity of FGFRs 1, 2, 3 and 4.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30807645",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In preclinical studies, high tumour FGFR mRNA expression predicted response to rogaratinib, an oral pan-FGFR inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31405822",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}